
    
      Subjects will be randomized and assigned to one of the treatment groups (D2 or D3). Subjects
      will be dispensed a supply of 1.25 mg cholecalciferol/ergocalciferol tablets, depending on
      their randomization outcome. The number of pills dispensed and medication instructions will
      be determined by their 25OHD level and K/DOQI guidelines. Both Study personnel and subject
      will be blinded to randomization group.

      The treatment phase will be 24 weeks in duration with lab visits every 6 weeks. All
      laboratory specimens will be drawn either at CCF Main hospital labs or at a CCF family Health
      center lab. Subjects will be have telephone interviews at week 4, 10, 16, 22 and possibly at
      weeks 28 and 34.
    
  